Biotech · Private company · Brooklyn, NY, US
Xylyx Bio, Inc.
Track this companyFree. Adds Xylyx Bio, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials0None registered
Pipeline programs0None found yet
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
NIH awards8
- Multi-organ metastatic breast cancer cell-based assay platform that models organotropic metastases using patient organoids in human tissue-derived ECMs to accelerate anti-metastatic drug developmentFiscal year 2026 · $1MNIH RePORTER 5R44CA287881-03 · fetched Nov 12, 2026
- Liver fibrosis cell-based assay platform: integrating patient-derived fibrotic liver ECM with primary stellate cells, Kupffer cells, and hepatocytes to accelerate anti-fibrotic drug developmentFiscal year 2026 · $956.6KNIH RePORTER 5R44DK139877-03 · fetched Nov 12, 2026
- Translational development and clinical evaluation of a bioengineered human lung graft for clinical transplantationFiscal year 2026 · $1.5MNIH RePORTER 5R44HL182545-02 · fetched Nov 12, 2026
- Translational development and clinical evaluation of a bioengineered human lung graft for clinical transplantationFiscal year 2025 · $1.5MNIH RePORTER 1R44HL182545-01 · fetched Nov 12, 2026
- Liver fibrosis cell-based assay platform: integrating patient-derived fibrotic liver ECM with primary stellate cells, Kupffer cells, and hepatocytes to accelerate anti-fibrotic drug developmentFiscal year 2025 · $967.7KNIH RePORTER 4R44DK139877-02 · fetched Nov 12, 2026
- Multi-organ metastatic breast cancer cell-based assay platform that models organotropic metastases using patient organoids in human tissue-derived ECMs to accelerate anti-metastatic drug developmentFiscal year 2025 · $966.4KNIH RePORTER 5R44CA287881-02 · fetched Nov 12, 2026
- Multi-organ metastatic breast cancer cell-based assay platform that models organotropic metastases using patient organoids in human tissue-derived ECMs to accelerate anti-metastatic drug developmentFiscal year 2024 · $295.6KNIH RePORTER 1R44CA287881-01A1 · fetched Nov 12, 2026
- Liver fibrosis cell-based assay platform: integrating patient-derived fibrotic liver ECM with primary stellate cells, Kupffer cells, and hepatocytes to accelerate anti-fibrotic drug developmentFiscal year 2024 · $370KNIH RePORTER 1R44DK139877-01A1 · fetched Nov 12, 2026